Tang Capital Management LLC reduced its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 90.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 221,716 shares of the company's stock after selling 2,186,084 shares during the quarter. Tang Capital Management LLC owned approximately 0.61% of iTeos Therapeutics worth $1,703,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of iTeos Therapeutics in the fourth quarter worth $42,000. Virtus ETF Advisers LLC increased its position in iTeos Therapeutics by 58.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock worth $69,000 after purchasing an additional 3,293 shares during the last quarter. Forefront Analytics LLC purchased a new stake in shares of iTeos Therapeutics during the 4th quarter worth about $85,000. Graham Capital Management L.P. purchased a new stake in shares of iTeos Therapeutics during the 4th quarter worth about $85,000. Finally, Clear Harbor Asset Management LLC acquired a new stake in shares of iTeos Therapeutics during the 4th quarter valued at about $96,000. 97.16% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the transaction, the insider now owns 2,108,594 shares in the company, valued at approximately $16,995,267.64. The trade was a 23.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the completion of the sale, the insider now owns 3,452,797 shares of the company's stock, valued at approximately $27,829,543.82. The trade was a 23.01% decrease in their position. The disclosure for this sale can be found here. Company insiders own 12.50% of the company's stock.
iTeos Therapeutics Price Performance
NASDAQ:ITOS traded up $0.03 during midday trading on Friday, reaching $8.72. The stock had a trading volume of 290,106 shares, compared to its average volume of 567,190. The stock has a market capitalization of $333.56 million, a P/E ratio of -2.77 and a beta of 1.39. iTeos Therapeutics, Inc. has a 1-year low of $4.80 and a 1-year high of $18.13. The firm's fifty day simple moving average is $6.70 and its 200-day simple moving average is $7.41.
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.14. On average, equities research analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on the company. Leerink Partners restated a "market perform" rating and issued a $9.00 price objective (down previously from $47.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. JPMorgan Chase & Co. lowered shares of iTeos Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $15.00 to $8.00 in a research note on Tuesday, May 13th. Wells Fargo & Company restated an "overweight" rating and set a $13.00 price target (down previously from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Piper Sandler reiterated an "overweight" rating and issued a $12.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Finally, Raymond James set a $12.00 target price on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, iTeos Therapeutics currently has a consensus rating of "Hold" and an average target price of $17.86.
Get Our Latest Research Report on iTeos Therapeutics
iTeos Therapeutics Profile
(
Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
See Also
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
